Drug Profile
CRE 319 M2
Alternative Names: CRE 319M2Latest Information Update: 02 May 2007
Price :
$50
*
At a glance
- Originator Cermol
- Class Anti-ischaemics; Antiarrhythmics; Small molecules
- Mechanism of Action Potassium channel modulators; Sodium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 05 Feb 2001 Phase-I clinical trials for Cardiovascular disorders (Unknown route)
- 18 Aug 1998 Preclinical development for Cardiovascular disorders in Germany (Unknown route)
- 18 Aug 1998 Preclinical development for Cardiovascular disorders in Spain (Unknown route)